Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CET

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN, INC.
03/24 AMGEN, INC. (NASDAQ : AMGN) Amgevita Approved By The European Commission Giving ..
03/23 AMGEN : European Commission Approves AMGEVITA(TM) (Biosimilar Adalimumab) For Th..
03/21 AMGEN INC. : (AMGN) Sank To A 1-Month Low After Repatha Study
03/20 ESPERION THERAPEUTICS INC (NASDAQ : ESPR): Get It While It’s Cheap
03/19 AMGEN : Analyses Of PCSK9 Inhibitor Prescription Rejection Rates Demonstrate Sig..
03/18 AMGEN : Lowering LDL Levels With Repatha® (Evolocumab) Did Not Adversely Affect ..
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17 Amgen and AXT slump while Adobe and Tiffany advance
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
More news
Sector news : Bio Therapeutic Drugs
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
03/14 AstraZeneca ovarian cancer drug slows disease markedly in study
03/09 Bull market turns 8 - historical facts and figures
03/08 Compare and contrast - Trump's tweets vs private comments to CEOs
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/24 Industry And Dark Pool Traders Bearish On Amgen
03/24 FDA Decision For Dupixent As Novartis Drives Its CAR-T
03/24 Scenarios For The Healthcare Bill - Cramer's Mad Money (3/23/17)
03/23 Amgen's Humira biosimilar OK'd in Europe
03/21 ABBVIE : Good For Value, Good For Growth
Advertisement
Financials ($)
Sales 2017 23 012 M
EBIT 2017 11 705 M
Net income 2017 8 097 M
Finance 2017 1 921 M
Yield 2017 2,72%
P/E ratio 2017 15,17
P/E ratio 2018 14,67
EV / Sales 2017 5,23x
EV / Sales 2018 4,62x
Capitalization 122 281 M
More Financials
Chart AMGEN, INC.
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 186 $
Spread / Average Target 12%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.13.36%122 281
CELGENE CORPORATION6.59%95 861
GILEAD SCIENCES, INC.-5.73%88 214
REGENERON PHARMACEUTIC..1.61%38 722
ACTELION LTD24.44%29 697
VERTEX PHARMACEUTICALS..22.14%22 123
More Results